Explore ›
Finding
Finding
adverse
OnabotulinumtoxinA caused significantly more urinary tract infections (33% vs 13%, P<0.001) and need for catheterization at 2 months (5% vs 0%, P=0.01) compared to anticholinergic therapy, reflecting transient urinary retention from the injection.
| Effect size | 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months |
| Comparator | Anticholinergic therapy (solifenacin 5-10 mg daily, with option to switch to trospium XR 60 mg) |
| Effect summary | adverse; 33% vs 13% for UTI; 5% vs 0% for catheterization at 2 months |
| Adverse events | urinary tract infection 33% vs 13%, 0 serious AEs |
Connected entities
Conditions
Source
PMC3543828
Anticholinergic Therapy vs. OnabotulinumtoxinA for Urgency Urinary Incontinence